Digest Network Come funziona
Network
/
Società
Ka
Non verificato

Kairos Pharma, Ltd

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

33 comunicati stampa

Guarda tutti i comunicati
21/08/2026
Finanza
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
22/07/2026
Mercato del lavoro
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
15/07/2026
Industria
Farmaceutica
Salute
Oncologia
Medicina - Varie
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
04/06/2026
Oncologia
Salute
Medicina - Varie
Scienza
Biotecnologia
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
14/05/2026
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
08/05/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
15/04/2026
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
02/03/2026
Mercato del lavoro
Software
Biotecnologia
Farmaceutica
Oncologia
Salute
Tecnica
Medicina - Varie
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
26/02/2026
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
20/01/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0